Home » Newsletters » BioWorld Science

BioWorld Science

Aug. 9, 2001

View Archived Issues

AxyS describes new serine protease inhibitor design technology

Ascorbic acid enhances arsenic trioxide potency in MM cells

Replagal receives European approval for Fabry's disease

Graffinity Pharmaceutical Design and Biosearch Italia form drug discovery alliance

Data from Metformin GR phase II trial reported by DepoMed

Lexicon Genetics and Immunex enter drug target validation agreement

Novel imino sugar inhibits HBV DNA replication without affecting DNA polymerase function

Lorus Therapeutics expands Virulizin clinical trial for pancreatic cancer

MedImmune begins Vitaxin phase I trials for rheumatoid arthritis

Guanfacine improves tic disorders and ADHD in children

Baxter to acquire Asta Medica Oncology

Bayer withdraws cerivastatin worldwide

FDA approves PEG-Intron for use with Rebetol

Trimeris and Array Biopharma sign drug discovery agreement

Sustained-release preparations of hypoglycemic drugs described by Ajinomoto

BVdU reported to be useful for inhibiting the growth of hyperproliferative cells

Cyclin-dependent kinase inhibitors identified by Bristol-Myers Squibb

Kyowa Hakko patents new compounds for treatment of urinary incontinence

Smooth muscle-relaxing agents reported by Kissei

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 5, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 5, 2025.
Epigenetic technology could eliminate misfolded prion proteins
BioWorld Science
The number of deaths caused by prion diseases reaches about 30,000 annually. Only 5 months pass from the diagnosis of seemingly healthy patients to the fatal...
Mesothelin is biomarker, potential target in arthritic bone damage
BioWorld Science
In a recent study published in Cell Reports Medicine, researchers from the Institute of Chinese Materia Medica of the China Academy of Chinese Medical Sciences...
Gene therapies aim for the big goal of edits in vivo
BioWorld Science
The field of gene therapy is experiencing major advances driven by precise editing technologies, such as base and prime editing, and by the design of increasingly...